JP2022532038A5 - - Google Patents
Info
- Publication number
- JP2022532038A5 JP2022532038A5 JP2021563262A JP2021563262A JP2022532038A5 JP 2022532038 A5 JP2022532038 A5 JP 2022532038A5 JP 2021563262 A JP2021563262 A JP 2021563262A JP 2021563262 A JP2021563262 A JP 2021563262A JP 2022532038 A5 JP2022532038 A5 JP 2022532038A5
- Authority
- JP
- Japan
- Prior art keywords
- administering
- combination
- pharmaceutical compositions
- therapeutic agent
- cell proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19171323 | 2019-04-26 | ||
| EP19171323.9 | 2019-04-26 | ||
| PCT/EP2020/061477 WO2020216911A1 (en) | 2019-04-26 | 2020-04-24 | Mrna formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532038A JP2022532038A (ja) | 2022-07-13 |
| JP2022532038A5 true JP2022532038A5 (https=) | 2023-04-24 |
| JP7650001B2 JP7650001B2 (ja) | 2025-03-24 |
Family
ID=66290283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563262A Active JP7650001B2 (ja) | 2019-04-26 | 2020-04-24 | ｍＲＮＡ製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362360A1 (https=) |
| EP (1) | EP3958893A1 (https=) |
| JP (1) | JP7650001B2 (https=) |
| KR (1) | KR20220023340A (https=) |
| CN (1) | CN114096272B (https=) |
| AU (1) | AU2020263948A1 (https=) |
| BR (1) | BR112021021262A2 (https=) |
| CA (1) | CA3138011A1 (https=) |
| IL (1) | IL287560B2 (https=) |
| MX (1) | MX2021013018A (https=) |
| SG (1) | SG11202111720TA (https=) |
| WO (1) | WO2020216911A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210386843A1 (en) * | 2019-01-04 | 2021-12-16 | Etherna Immunotherapies Nv | mRNA Vaccine |
| WO2020182993A1 (en) * | 2019-03-13 | 2020-09-17 | Etherna Immunotherapies Nv | Mrna vaccine |
| CN119701015A (zh) * | 2023-09-26 | 2025-03-28 | 深圳瑞吉生物科技有限公司 | 一种细胞因子mRNA组合药物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476419B2 (en) * | 2007-09-14 | 2013-07-02 | Vrije Universiteit Brussel | Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| EP2201100B1 (en) * | 2007-09-14 | 2016-03-16 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| HUE058792T2 (hu) | 2013-11-12 | 2022-09-28 | Univ Brussel Vrije | RNS-transzkripciós vektor és felhasználása |
| CN120842296A (zh) * | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| EP3359670B2 (en) * | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
-
2020
- 2020-04-24 KR KR1020217038364A patent/KR20220023340A/ko active Pending
- 2020-04-24 BR BR112021021262A patent/BR112021021262A2/pt unknown
- 2020-04-24 CA CA3138011A patent/CA3138011A1/en active Pending
- 2020-04-24 CN CN202080038101.1A patent/CN114096272B/zh active Active
- 2020-04-24 IL IL287560A patent/IL287560B2/en unknown
- 2020-04-24 WO PCT/EP2020/061477 patent/WO2020216911A1/en not_active Ceased
- 2020-04-24 AU AU2020263948A patent/AU2020263948A1/en active Pending
- 2020-04-24 MX MX2021013018A patent/MX2021013018A/es unknown
- 2020-04-24 US US17/604,559 patent/US20220362360A1/en active Pending
- 2020-04-24 JP JP2021563262A patent/JP7650001B2/ja active Active
- 2020-04-24 EP EP20721229.1A patent/EP3958893A1/en active Pending
- 2020-04-24 SG SG11202111720TA patent/SG11202111720TA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| EP4596041A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| JP2014530220A5 (https=) | ||
| JP2016147915A5 (https=) | ||
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2012193216A5 (https=) | ||
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| JP2022532038A5 (https=) | ||
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JP2020536085A5 (https=) | ||
| JP2016530291A5 (https=) | ||
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| JP2015537009A5 (https=) | ||
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| JP2013541583A5 (https=) | ||
| JP2015502926A5 (https=) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| JP2007119497A5 (https=) |